磁惊厥治疗抑郁症的确证性疗效与安全性试验(CREST-MST):通过神经生理学识别新型生物标志物的方案
CREST-MST是一项两中心、双盲、随机、非劣效性临床试验,旨在开发磁惊厥治疗作为难治性抑郁症的有效安全治疗。本神经生理学子研究拟评估两个生物标志物:通过TMS-EEG测量的皮层抑制预测自杀意念缓解(主要结局),通过静息态EEG多尺度熵分析预测认知损害(次要结局)。
要点
- CREST-MST为两中心、双盲、随机、非劣效性试验,开发磁惊厥治疗难治性抑郁症。
- 子研究评估TMS-EEG皮层抑制预测自杀意念缓解,静息态EEG复杂度预测认知损害。
- 初步研究显示皮层抑制与自杀意念缓解相关,静息态EEG复杂度与惊厥治疗后认知副作用程度相关。
核心结论
- 评估皮层抑制和脑时间动力学有助于理解抑郁症和自杀意念的病理生理学,并定义可帮助临床医生诊断和选择治疗的新的生物学靶点。
- 静息态EEG复杂度这一神经生理学指标可能帮助临床医生评估这些有用且有效治疗所引起的不良反应风险。
研究设计与样本
- 本神经生理学研究方案作为CREST-MST总体方案的配套文件发布,总体方案描述了两中心、双盲、随机、非劣效性临床试验,旨在开发磁惊厥治疗作为难治性抑郁症的有效且安全治疗。
- 本神经生理学部分旨在评估两个生物标志物:一个预测自杀意念缓解(主要结局),另一个预测认知损害(次要结局)。
- 自杀意念将通过皮层抑制评估,根据我们的初步研究,皮层抑制与自杀意念缓解相关;皮层抑制通过同步经颅磁刺激和脑电图(TMS-EEG)测量,TMS-EEG测量TMS诱发的EEG活动。
- 与惊厥治疗相关的认知不良反应将通过多尺度熵分析评估,该分析反映正在进行的静息态EEG活动的复杂性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Electroconvulsive therapy (ECT) is the most effective treatment for treatment-resistant depression (TRD), especially for acute suicidal ideation, but the associated cognitive adverse effects and negative stigma limit its use. Another seizure therapy under development is magnetic seizure therapy (MST), which could potentially overcome the restrictions associated with ECT with similar efficacy. The neurophysiological targets and mechanisms of seizure therapy, however, remain poorly understood. METHODS/DESIGN: This neurophysiological study protocol is published as a companion to the overall Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST-MST) protocol that describes our two-site, double-blind, randomized, non-inferiority clinical trial to develop MST as an effective and safe treatment for TRD. Our aim for the neurophysiological component of the study is to evaluate two biomarkers, one to predict remission of suicidal ideation (primary outcome) and the other to predict cognitive impairment (secondary outcome). Suicidal ideation will be assessed through cortical inhibition, which according to our preliminary studies, correlates with remission of suicidal ideation. Cortical inhibition will be measured with simultaneous transcranial magnetic stimulation (TMS) and electroencephalography (EEG), TMS-EEG, which measures TMS-evoked EEG activity. Cognitive adverse effects associated with seizure therapy, on the contrary, will be evaluated via multiscale entropy analysis reflecting the complexity of ongoing resting-state EEG activity. DISCUSSION: ECT and MST are known to influence cortical inhibition associated with depression, suicidal ideation severity, and clinical outcome. Therefore, evaluating cortical inhibition and brain temporal dynamics will help understand the pathophysiology of depression and suicidal ideation and define new biological targets that could aid clinicians in diagnosing and selecting treatments. Resting-state EEG complexity was previously associated with the degree of cognitive side effects after a seizure therapy. This neurophysiological metric may help clinicians assess the risk for adverse effects caused by these useful and effective treatments. TRIAL REGISTRATION: ClinicalTrials.gov NCT03191058 . Registered on June 19, 2017.
引用
- Daskalakis ZJ, McClintock SM, Hadas I, et al. Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST-MST): protocol for identification of novel biomarkers via neurophysiology. Trials. 2021. PMID: 34895296. doi:10.1186/s13063-021-05873-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。